Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.16587 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anti-transcription intermediary factor 1 gamma (TIF1-γ) antibody-positive dermatomyositis associated with adenocarcinoma of the ileocecal region: A first case report.
Asian J Surg
December 2024
Department of Neurology, Sir Run Run Hospital Nanjing Medical University, Nanjing, Jiangsu province, 211112, China. Electronic address:
Case Report: IVIG causing bilateral papilledema and increased intracranial hypertension in patients with anti-TIF-1γ antibody-positive JDM.
Front Pediatr
November 2024
Department of Pediatrics, Golisano Children's Hospital, University of Rochester, Rochester, NY, United States.
Juvenile dermatomyositis is a systemic autoimmune disease characterized by progressive proximal muscle weakness, pathognomonic rashes, and often the presence of myositis-specific antibodies. Consensus treatment plans for pediatric patients with juvenile dermatomyositis recommend steroids and methotrexate as initial therapy. Patients with anti-transcription intermediary factor 1 gamma (anti-TIF-1γ) antibodies tend to have more refractory disease requiring more aggressive treatment with intravenous immunoglobulin, which is typically well tolerated.
View Article and Find Full Text PDFA retrospective study for clinical characteristics of 293 patients with dermatomyositis.
Medicine (Baltimore)
November 2024
Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Article Synopsis
- The study examined clinical differences among various antibody phenotypes in 293 patients with dermatomyositis (DM) from 2018 to 2023.
- Key findings revealed that patients with anti-MDA5 antibodies were more likely to experience respiratory issues and fever, while those with anti-TIF1-γ antibodies had higher rates of malignancy and certain skin symptoms.
- Prognostic factors influencing survival included age at onset, presence of fever, eosinophil levels, and complement 3 levels, with specific impacts identified through statistical analysis.
Article Synopsis
- - The study aimed to analyze the frequency and relationship of two autoantibodies, anti-CCAR1 and anti-Sp4, in adult dermatomyositis (DM) patients and their link to cancer.
- - Researchers studied data from 305 anti-TIF1γ-positive DM patients at Johns Hopkins and Stanford, discovering that about one-third were positive for each antibody, with 20% positive for both.
- - Results indicated that those without anti-Sp4 or anti-CCAR1 had a stronger association with cancer, whereas patients positive for either antibody had a lower risk; nevertheless, half of the patients were negative for both and may need closer cancer monitoring.
Anti-transcription intermediate factor 1-γ antibody-positive dermatomyositis with refractory skin ulcers and rapid cancer progression.
J Dermatol
September 2024
Department of Dermatology, Shiga University of Medical Science, Otsu, Shiga, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!